OPZELURA

This brand name is authorized in Austria, Estonia, France, Croatia, Ireland, Italy, Lithuania, United Kingdom, United States

Active ingredients

The drug OPZELURA contains one active pharmaceutical ingredient (API):

1 Ruxolitinib UNII 82S8X8XX8H - RUXOLITINIB

Ruxolitinib is a selective inhibitor of the Janus Associated Kinases (JAKs) JAK1 and JAK2 (IC50 values of 3.3 nM and 2.8 nM for JAK1 and JAK2 enzymes, respectively). These mediate the signalling of a number of cytokines and growth factors that are important for haematopoiesis and immune function. Ruxolitinib inhibits cytokine-induced STAT3 phosphorylation in whole blood from healthy subjects, MF patients and PV patients. Read about Ruxolitinib

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
D11AH09		D Dermatologicals → D11 Other dermatological preparations → D11A Other dermatological preparations → D11AH Agents for dermatitis, excluding corticosteroids
Discover more medicines within D11AH09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1888331
Country: FR	Base de données publique des médicaments	Identifier(s): 68279528
Country: IT	Agenzia del Farmaco	Identifier(s): 050666015
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1097002, 1097302
Country: US	FDA, National Drug Code	Identifier(s): 50881-007